RecruitingNot ApplicableNCT02734602

Imaging SV2A in Mood Disorders

Sponsor

Yale University

Enrollment

130 participants

Start Date

Apr 1, 2016

Study Type

INTERVENTIONAL

Conditions

Post Traumatic Stress Disorder Major Depressive Disorder

Summary

This study is designed to examine SV2A density in MDD and PTSD as a correlate of synaptic density, and to determine whether ketamine administration will reverse the synaptic loss in vivo in human subjects. To our knowledge, this is the first human study to examine SV2A in vivo in MDD and PTSD and to use the first known drug (ketamine) that rapidly reverses synaptic loss to determine whether ketamine administration could restore some of the structural changes associated with depression and PTSD. After a screening process to determine eligibility, all subjects will participate in an MRI, and 2-3 PET scans with the administration of ketamine for one of the scans. Cognitive testing and a stress test may also be done on scan days.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is using a specialized brain scan (PET scan) to look at a protein called SV2A in the brains of people with mood disorders — including depression, bipolar disorder, and PTSD — to better understand how brain chemistry differs in these conditions and how treatments like ketamine affect it. **You may be eligible if...** - You are between 18 and 70 years old and speak English - You have a diagnosis of major depressive disorder (with a current depressive episode), bipolar disorder, PTSD, or are a healthy volunteer with no psychiatric history - If you are in the ketamine group: you are currently receiving ketamine infusions for treatment-resistant depression **You may NOT be eligible if...** - You have more than one psychiatric diagnosis (outside of the specific condition required for your group) - You are pregnant - You have significant neurological or medical conditions that could affect the scan results Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.